{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:43:08Z","timestamp":1762522988389,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Sailing Program","award":["21YF1438600"],"award-info":[{"award-number":["21YF1438600"]}]},{"name":"Incubation Project of Shanghai Pulmonary Hospital","award":["fkzr2109"],"award-info":[{"award-number":["fkzr2109"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900421","82203635"],"award-info":[{"award-number":["81900421","82203635"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR4028"],"award-info":[{"award-number":["SHDC2020CR4028"]}]},{"name":"the project from the Science and Technology Commission of Shanghai Municipality","award":["23ZR1453200"],"award-info":[{"award-number":["23ZR1453200"]}]},{"name":"\u201cYouth Cultivation\u201d Project of Shanghai Pulmonary Hospital","award":["Fkxr2303"],"award-info":[{"award-number":["Fkxr2303"]}]},{"name":"the Shanghai Rising Star Program","award":["20QA1408300"],"award-info":[{"award-number":["20QA1408300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-17767-y","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:34:23Z","timestamp":1751967263000},"page":"7874-7882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes After Neoadjuvant Targeted Therapy in Patients with ALK or ROS1 Rearrangement Locally Advanced Non-small Cell Lung Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Zhao","family":"An","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"3","key":"17767_CR1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.21037\/tlcr-21-39","volume":"10","author":"Z Hao","year":"2021","unstructured":"Hao Z, Liang H, Zhang Y, et al. Surgery for advanced-stage non-small cell lung cancer: lobectomy or sub-lobar resection? Transl Lung Cancer Res. 2021;10(3):1408\u201323.","journal-title":"Transl Lung Cancer Res."},{"key":"17767_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-13-158","volume":"13","author":"SH Jafri","year":"2013","unstructured":"Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158.","journal-title":"BMC Cancer."},{"issue":"5","key":"17767_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/1753465816660925","volume":"10","author":"RB Lim","year":"2016","unstructured":"Lim RB. End-of-life care in patients with advanced lung cancer. Ther Adv Respir Dis. 2016;10(5):455\u201367.","journal-title":"Ther Adv Respir Dis."},{"issue":"12","key":"17767_CR4","doi-asserted-by":"publisher","first-page":"e009419","DOI":"10.1136\/bmjopen-2015-009419","volume":"5","author":"H Fan","year":"2015","unstructured":"Fan H, Shao ZY, Xiao YY, et al. Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. BMJ Open. 2015;5(12):e009419.","journal-title":"BMJ Open."},{"key":"17767_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.lungcan.2022.08.014","volume":"172","author":"D Sentana-Lledo","year":"2022","unstructured":"Sentana-Lledo D, Viray H, Piper-Vallillo AJ, et al. Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer. Lung Cancer. 2022;172:124\u20136.","journal-title":"Lung Cancer."},{"key":"17767_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","volume":"178","author":"C Lv","year":"2023","unstructured":"Lv C, Fang W, Wu N, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer. 2023;178:151\u20136.","journal-title":"Lung Cancer."},{"issue":"10026","key":"17767_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387(10026):1415\u201326.","journal-title":"Lancet."},{"issue":"6","key":"17767_CR8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","volume":"131","author":"K Rikova","year":"2007","unstructured":"Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190\u2013203.","journal-title":"Cell."},{"issue":"7153","key":"17767_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature."},{"issue":"22","key":"17767_CR10","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","volume":"36","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018;36(22):2251\u20138.","journal-title":"J Clin Oncol."},{"issue":"25","key":"17767_CR11","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med."},{"issue":"6","key":"17767_CR12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","volume":"198","author":"M Alexander","year":"2020","unstructured":"Alexander M, Kim SY, Cheng H. Update 2020: Management of non-small cell lung cancer. Lung. 2020;198(6):897\u2013907.","journal-title":"Lung."},{"issue":"12","key":"17767_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40265-019-01164-3","volume":"79","author":"TA Morris","year":"2019","unstructured":"Morris TA, Khoo C, Solomon BJ. Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors. Drugs. 2019;79(12):1277\u201386.","journal-title":"Drugs."},{"issue":"21","key":"17767_CR14","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Medi. 2014;371(21):1963\u201371.","journal-title":"N Engl J Medi."},{"issue":"20","key":"17767_CR15","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/1759-7714.14112","volume":"12","author":"S Zhao","year":"2021","unstructured":"Zhao S, Zhu S, Lei X, et al. Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: a case report. Thorac Cancer. 2021;12(20):2815\u20138.","journal-title":"Thorac Cancer."},{"issue":"11","key":"17767_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1200\/JCO.20.03025","volume":"39","author":"R Dziadziuszko","year":"2021","unstructured":"Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 2021;39(11):1253\u201363.","journal-title":"J Clin Oncol."},{"issue":"4","key":"17767_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang C, Li SL, Nie Q, et al. Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement. J Thorac Oncol. 2019;14(4):726\u201331.","journal-title":"J Thorac Oncol."},{"issue":"5","key":"17767_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cllc.2023.03.008","volume":"24","author":"F Lococo","year":"2023","unstructured":"Lococo F, Cancellieri A, Chiappetta M, et al. Salvage surgery after first-line alectinib for locally-advanced\/metastatic ALK-rearranged NSCLC: pathological response and perioperative results. Clin Lung Cancer. 2023;24(5):467\u201373.","journal-title":"Clin Lung Cancer."},{"issue":"2","key":"17767_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"5","key":"17767_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis WD, Dacic S, Wistuba I, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020;15(5):709\u201340.","journal-title":"J Thorac Oncol."},{"issue":"10","key":"17767_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","volume":"15","author":"AL Moreira","year":"2020","unstructured":"Moreira AL, Ocampo PSS, Xia Y, et al. A grading system for invasive pulmonary adenocarcinoma: a proposal from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020;15(10):1599\u2013610.","journal-title":"J Thorac Oncol."},{"key":"17767_CR22","doi-asserted-by":"publisher","first-page":"1034897","DOI":"10.3389\/fonc.2023.1034897","volume":"13","author":"Y Xiong","year":"2023","unstructured":"Xiong Y, Bian D, Huang Z, et al. The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations:a retrospective analysis based on single center. Front Oncol. 2023;13:1034897.","journal-title":"Front Oncol."},{"key":"17767_CR23","doi-asserted-by":"publisher","first-page":"912153","DOI":"10.3389\/fphar.2022.912153","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Ren S, Yang L, et al. Osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer: a case series. Front Pharmacol. 2022;13:912153.","journal-title":"Front Pharmacol."},{"issue":"2","key":"17767_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","volume":"161","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Fu F, Hu H, et al. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: a phase II study. J Thorac Cardiovasc Surg. 2021;161(2):434-42 e432.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"2","key":"17767_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1634\/theoncologist.2018-0120","volume":"24","author":"L Xiong","year":"2019","unstructured":"Xiong L, Li R, Sun J, et al. Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm, phase II study. Oncologist. 2019;24(2):157\u201364.","journal-title":"Oncologist."},{"issue":"15","key":"17767_CR26","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/1759-7714.14558","volume":"13","author":"S Mai","year":"2022","unstructured":"Mai S, Wang Y, Wang X, et al. Neoadjuvant ceritinib treatment in ALK-rearranged locally advanced adenosquamous carcinoma: a case report. Thorac Cancer. 2022;13(15):2275\u20138.","journal-title":"Thorac Cancer."},{"key":"17767_CR27","doi-asserted-by":"publisher","first-page":"655856","DOI":"10.3389\/fonc.2021.655856","volume":"11","author":"XH Xie","year":"2021","unstructured":"Xie XH, Zhan ZJ, Qin YY, et al. Case report: neoadjuvant and adjuvant crizotinib targeted therapy in stage IIIA-N2 ALK-positive non-small-cell lung cancer. Front Oncol. 2021;11:655856.","journal-title":"Front Oncol."},{"issue":"5","key":"17767_CR28","doi-asserted-by":"publisher","first-page":"ezad313","DOI":"10.1093\/ejcts\/ezad313","volume":"64","author":"LL Wu","year":"2023","unstructured":"Wu LL, Lin WK, Qian JY, et al. Prognostic assessment of lung adenocarcinoma patients with early-staging diseases: a nomogram based on coagulation-related factors. Eur J Cardiothorac Surg. 2023;64(5):ezad313.","journal-title":"Eur J Cardiothorac Surg."},{"issue":"22","key":"17767_CR29","doi-asserted-by":"publisher","first-page":"12244","DOI":"10.3390\/ijms222212244","volume":"22","author":"T Marjanski","year":"2021","unstructured":"Marjanski T, Dziedzic R, Kowalczyk A, Rzyman W. Safety of surgery after neoadjuvant targeted therapies in non-small cell lung cancer: a narrative review. Int J Mol Sci. 2021;22(22):12244.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"17767_CR30","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.1038\/s41598-023-34397-0","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang B, Song Y, Chen Z, et al. A retrospective study of postoperative targeted therapy in ALK-positive lung cancer. Scientific Rep. 2023;13(1):8317.","journal-title":"Scientific Rep."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17767-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17767-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17767-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:05:52Z","timestamp":1758549952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17767-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17767"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17767-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}